Transmucosal Delivery of Linagliptin for the Treatment of Type- 2 Diabetes Mellitus by Ultra-Thin Nanofibers

E-ISSN： 1875-5704|12|3|323-332

ISSN： 1567-2018

Source： Current Drug Delivery, Vol.12, Iss.3, 2015-06, pp. : 323-332

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Linagliptin: In Type 2 Diabetes Mellitus

By Scott Lesley J.

Drugs, Vol. 71, Iss. 5, 2011-03 ,pp. : 611-624

Adis International

Access to resources Recommend Favorite

Linagliptin for the treatment of type 2 diabetes

By Del Prato Stefano

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 17, 2011-12 ,pp. : 2759-2762

Informa Healthcare

Access to resources Recommend Favorite

Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation)

By Scheen André J

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 12, 2011-12 ,pp. : 1561-1576

Informa Healthcare

Access to resources Recommend Favorite

Linagliptin: A Review of its Use in the Management of Type 2 Diabetes Mellitus

By Deeks Emma D.

Drugs, Vol. 72, Iss. 13, 2012-09 ,pp. : 1793-1824

Adis International

Access to resources Recommend Favorite

Linagliptin: a guide to its use in type 2 diabetes mellitus

By Scott Lesley J. Lyseng-Williamson Katherine A.

Drugs & Therapy Perspectives, Vol. 28, Iss. 5, 2012-05 ,pp. : 1-5

Adis International

Access to resources Recommend Favorite